午夜电影在线观看国产1区|国产在线19禁免费观看国产|最近更新中文字幕2019视频|久久 _996热re视频精品视频这里-国产黄视频在线播放-国产最新精品亚洲2024不卡-久久久香

Kolupin? (tunlametinib) has been officially included in China's new National Reimbursement Drug List.

Kolupin? (tunlametinib) is approved for marketing by the NMPA.

Kechow Pharma and Sinopharm Global Procurement signed a strategic cooperation agreement.

HL-085, a single agent targeting NRAS-mutant melanoma, qualified for priority review approval.

HL-085 was included in the 2023 CSCO guidelines as a Class I recommendation for second-line treatment of NRAS-mutant melanoma.

Shanghai Kechow Pharma was honored as the “2023 Zhangjiang Bio-health Industry Emerging Company of the Year.”

The Kechow Pharma animal experiment center was officially opened in Tianjin. 

HL-085, a single agent for NRAS-melanoma, successfully completed pivotal registration clinical studies and submitted its NDA.

HL-003 received IND approval and entered Phase I clinical trials.

Ranked among the 2022 Top 100 Pharmaceutical Innovation Seed Enterprises in China.

Entered into a strategic partnership with Roche Pharmaceuticals and obtained the marketing rights for Zobovol? in mainland China.

HL-085, combined with vemurafenib combination therapy, entered into Phase Ib study.

Built a new laboratory with a total area of 1,800 square meters in Tianjin.

Entered the preparatory stage for a formulation plant.

Entered the preparatory stage for the launch of Zelboraf? in China.

Established the Beijing branch of Shanghai Kechow Pharma.

Committed to two major national scientific and technological programs for the creation and manufacture of new drugs.

M31 Capital and SZV Capital entered the company.

HL-085, a single drug, entered into Phase II clinical trials. 

HL-085 entered Phase I clinical trials.

Received Series B investment from SIC Venture Pangaea Venture Capital.

HL085 entered Phase I clinical trials.

HL-085 and vemurafenib combination therapy entered Phase I clinical trials.

Received Series C investment from Decheng Capital, Qiming, and Sherpa.

HL-085 received U.S. FDA clinical approval.

Established Shanghai Kechow Pharma , Inc.

Obtained Pre-A investment from Eli Lilly and Morningside.

Completed preclinical studies for HL-085, the company's new class 1.1 anticancer drug.

Received Series A investment from China Ridge Capital, Pangu Venture Capital, Jianxin, and Yuansheng.

Founded the Tianjin company, focusing on small-molecule antitumor drug research and development.